These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31013813)

  • 1. When CAR Meets Stem Cells.
    Lee JM
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.
    Cao H; Sugimura R
    Cancer Treat Res; 2022; 183():255-274. PubMed ID: 35551663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 10. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.
    Tempero M
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1179. PubMed ID: 28982741
    [No Abstract]   [Full Text] [Related]  

  • 11. Modelling CAR-T therapy in humanized mice.
    Wu Y; Yu XZ
    EBioMedicine; 2019 Feb; 40():25-26. PubMed ID: 30665855
    [No Abstract]   [Full Text] [Related]  

  • 12. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
    Morgan MA; Schambach A
    Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
    Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
    Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

  • 18. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
    Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
    J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.